

ASX: EIQ RELEASE 10 September 2024

INVESTOR WEBINAR

Highlights:

 Echo IQ will hold an investor webinar at 11:00am AEST on Thursday 12 September 2024, hosted by Chief Commercial Officer, Mr. Deon Strydom and Chief Research and Strategy Officer, Professor Geoff Strange

- Webinar follows the Company's presentation of groundbreaking study results at the world's largest cardiology congress in London, UK
- Additional details to be provided around Company's regulatory and commercialisation pathways

Sydney: Artificial Intelligence and Medical Technology company Echo IQ Limited ("the Company") (ASX:EIQ) is pleased to advise that it will host an investor webinar at 11:00am AEST on Thursday, 12 September 2024 at which Chief Commercial Officer, Mr Deon Strydom, and Chief Research and Strategy Officer, Professor Geoff Strange, will provide an update to investors.

The webinar follows the Company's recent presentation of results from clinical studies relating to its new algorithm for heart failure. Echo IQ was featured in two late-breaking science presentations at the European Society of Cardiology (ESC) Congress 2024, the world's largest and most renowned cardiology conference.

During the webinar, the Company will also provide an update on regulatory and commercialisation pathways. The briefing will be followed by a Q&A Session. Questions can be submitted now to investors@echoiq.ai.

Anyone wishing to attend the webinar must register in advance using the below link.

Webinar Details

Date and time: 11:00am AEST (09:00am AWST) on Thursday, 12 September 2024

Register via: https://us02web.zoom.us/webinar/register/WN_PfxHTwRWSxudoIbZx_MNDA

- ENDS -



Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries:

Philip Woolff, Chief Operating Officer philip.woolff@echoiq.ai / marketing@echoiq.ai / +61 (0)490 030 620

Investor Enquiries:

Andrew Grover, Executive Chair

<u>Andrew.grover@echoiq.ai</u> / <u>investor@echoiq.ai</u>

ABOUT ECHO IQ

Echo IQ uses Al-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

